Raiffeisen Bank International AG Sells 10,050 Shares of IDEXX Laboratories, Inc. $IDXX

Raiffeisen Bank International AG trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,567 shares of the company’s stock after selling 10,050 shares during the quarter. Raiffeisen Bank International AG owned about 0.06% of IDEXX Laboratories worth $31,091,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of IDXX. Elyxium Wealth LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $3,666,459,000. Northwestern Mutual Wealth Management Co. increased its position in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares during the period. Norges Bank bought a new position in IDEXX Laboratories during the fourth quarter worth about $332,265,000. JPMorgan Chase & Co. increased its position in IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after acquiring an additional 326,348 shares during the period. Finally, Zurich Insurance Group Ltd FI bought a new position in IDEXX Laboratories during the third quarter worth about $143,730,000. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on IDXX. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. UBS Group decreased their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup initiated coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Price Performance

IDXX stock opened at $557.91 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The firm has a market cap of $44.01 billion, a P/E ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55. The company’s 50-day moving average price is $563.14 and its two-hundred day moving average price is $628.16.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the firm earned $2.91 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.